NextCure, Inc.
Biopharma roundup reported FDA/EC approvals and trial updates for Lantheus (LNTH) TAUKLARIFY, Ceribell (CBLL) AI EEG algorithms, Labcorp (LH) PGDx CDx, and EU/UK approvals for Galderma (GDERF) Restylane Shaype and Rhythm (RYTM) IMCIVREE. GRAIL (GRAL) faces an FDA panel on Sept. 23. Teledyne (TDY) to buy Varex (VREX) for about $1.1B; Aura (AURA) cut 20% staff.
Simcere Zaiming, Inc. sold 30,000 indirectly-held shares of NextCure, Inc. (NXTC) at $6.16 ($0.18M total) on 2026-08-10.
RTW Biotech Opportunities said its portfolio company Avere Therapeutics will merge with NextCure Inc. in an all-stock deal expected to close by year-end. The combined firm will trade on Nasdaq as Avere Therapeutics under AVRX. Avere plans $820M in private placements, including $5.9M from Avere, to fund AVR-001 Phase 2b psoriasis, Phase 3 psoriasis, and Phase 2b ulcerative colitis.
Over the past 7 days, alphai's AI scored 3 news stories mentioning NXTC (NextCure, Inc.). Coverage has skewed bullish: 1 bullish, 2 neutral, and 0 bearish.
Recent NXTC coverage spans mergers & acquisitions, insider activity and financial news.
In the last 30 days, NXTC insiders filed 14 SEC Form 4 transactions — 13 purchases ($1.7M) and 1 sale ($185K). The most active reporter was ADAR1 Capital Management, LLC with 13 filings.
The merger announcement is a valuation and corporate-action catalyst for NextCure, with terms likely to drive trading.
This is an insider-related indirect sale with no 10b5-1 plan stated, but it is not a fundamental company disclosure.
Deal terms and expected close date create a near-term re-rating risk for NXTC holders, with execution and financing details driving sentiment.
Deal mechanics and timing can re-rate NXTC on deal certainty, funding structure, and post-merger pipeline value.
NXTC is effectively a merger vehicle into Avere, with near-term focus on closing conditions, cash burn, and asset monetization.
alphai scores every news story that mentions NXTC with an AI model for sentiment and relevance, and aggregates insider trades from NextCure, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Biopharma roundup reported FDA/EC approvals and trial updates for Lantheus (LNTH) TAUKLARIFY, Ceribell (CBLL) AI EEG algorithms, Labcorp (LH) PGDx CDx, and EU/UK approvals for Galderma (GDERF) Restylane Shaype and Rhythm (RYTM) IMCIVREE. GRAIL (GRAL) faces an FDA panel on Sept. 23. Teledyne (TDY) to buy Varex (VREX) for about $1.1B; Aura (AURA) cut 20% staff.
7 min readSimcere Zaiming, Inc. sold 30,000 indirectly-held shares of NextCure, Inc. (NXTC) at $6.16 ($0.18M total) on 2026-08-10.
2 min readRTW Biotech Opportunities said its portfolio company Avere Therapeutics will merge with NextCure Inc. in an all-stock deal expected to close by year-end. The combined firm will trade on Nasdaq as Avere Therapeutics under AVRX. Avere plans $820M in private placements, including $5.9M from Avere, to fund AVR-001 Phase 2b psoriasis, Phase 3 psoriasis, and Phase 2b ulcerative colitis.
3 min readRTW Biotech Opportunities said private portfolio company Avere Therapeutics will go public via an all-stock reverse merger with NextCure Inc., expected by year-end. Avere plans $320 million and $500 million private placements totaling $820 million. The combined company will trade on Nasdaq as Avere Therapeutics, Inc. under ticker AVRX, funding AVR-001 through psoriasis Phase 2b and Phase 3, and ulcerative colitis Phase 2b.
4 min readNextCure (NXTC) reported Q2 2026 net loss of $14.9M, narrower than $26.8M a year earlier, with lower R&D and G&A expenses. It also recorded $5.1M asset impairments. NextCure said its all-stock merger with Avere Therapeutics is expected to close in H2 2026, with the combined firm trading as AVRX and Avere pursuing about $320M gross private financing.
5 min readNextCure, Inc. (NXTC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 nxtc-20260806xex99d1.htm EX-99.1 Exhibit 99.1 NextCure Provides Business Update and Reports Second Quarter 2026 Financial Results – Announced Proposed Merger with Avere Therapeutics – Preserving Capital in Support of Merger Closing; Continuing Clinical Transition and
6 min readADAR1 Capital Management, LLC purchased 329,153 indirectly-held shares of NextCure, Inc. (NXTC) at an average of $4.93 ($4.80–$5.00, $1.62M total) across 9 trades over 2026-07-30 to 2026-07-31.
2 min readADAR1 Capital Management, LLC purchased 17,608 indirectly-held shares of NextCure, Inc. (NXTC) at an average of $4.98 ($4.95–$5.00) across 4 trades over 2026-07-27 to 2026-07-29.
2 min readBiotech stocks rose Tuesday. NextCure (NXTC) jumped over 200% on a definitive all-stock merger with Avere Therapeutics, expected to close in 2H 2026, with the combined firm trading as AVRX. Basel Medical (BMGL) gained 26% after regaining Nasdaq bid-price compliance. Outlook Therapeutics (OTLK) rose 11% ahead of an FDA decision on July 29, 2026. Other gainers included DYAI, NUWE, ATAI, and QNCX.
2 min readNextCure (NASDAQ:NXTC) agreed to merge with Avere Therapeutics, forming Avere Therapeutics on Nasdaq as AVRX. The deal targets development of AVR-001, a once-weekly oral IL-23 therapy. Financing totals $320M, including $251M convertible notes. Proceeds fund Phase 2b/3 psoriasis and Phase 2b ulcerative colitis trials. NXTC shares rose 198.63% to $6.51.
4 min read
